Mabwell – Talk Bio

Actionable Insights Powered by AI

Aditum forms new company for China-sourced asset in $1B deal

3 weeks ago talkbio0Tagged Aditum, biotech licensing, China-sourced asset, cross-border pharma, Dyslipidemias, Mabwell, newco, Vascular Diseases

Aditum; China-sourced asset; $1B deal; newco; Mabwell; dyslipidemia; vascular disorders; biotech licensing; cross-border pharma

Alphabet’s Calico Strikes $596M Deal for Mabwell’s Anti-Aging Antibody

4 months ago talkbio0Tagged aging-related diseases, Alphabet, Antibodies, Biopharma, Calico, interleukin-11, Licensing, Mabwell

Calico; Alphabet; Mabwell; anti-aging; biotech; IL-11 antibody; 9MW3811; exclusive licensing; aging-related diseases; biopharma deal